Prostate Health [2026]: What Men Over 40 Actually Need to Know

The prostate gland causes more medical conversations among men over 40 than almost any other organ. Prostate cancer is the most common cancer in men (excluding skin cancer) in the United States. Benign prostatic hyperplasia (BPH, enlarged prostate) affects over 50% of men by age 60. Understanding what the evidence shows about these conditions — and where it doesn't support the conventional wisdom — is worth the effort.

Benign Prostatic Hyperplasia: The Common, Non-Cancerous Problem

BPH is a non-cancerous enlargement of the prostate that affects urinary function by compressing the urethra as it passes through the gland. Symptoms — urinary urgency, frequency (particularly at night), weak stream, difficulty starting urination, and incomplete bladder emptying — are collectively called lower urinary tract symptoms (LUTS). BPH is not prostate cancer and does not increase cancer risk.

The natural history of BPH is variable: some men experience significant symptom progression over time; others have stable or even improving symptoms without treatment. For mild symptoms, watchful waiting with lifestyle modifications is appropriate. Reducing fluid intake in the evenings, limiting caffeine and alcohol (both of which increase urinary urgency), and practicing double-voiding (urinating, waiting a few minutes, then urinating again to empty the bladder more completely) can meaningfully reduce symptom burden.

For moderate-to-severe symptoms, alpha-blocker medications (tamsulosin/Flomax, alfuzosin) relax the smooth muscle of the prostate and bladder neck, improving urinary flow within days of starting treatment. 5-alpha reductase inhibitors (finasteride, dutasteride) shrink the prostate over 6-12 months and are most beneficial for men with large prostates. Combination therapy is used for significant symptoms with large prostates.

Prostate Cancer Screening: The Contested PSA Question

PSA (prostate-specific antigen) testing is the primary screening tool for prostate cancer and one of the most debated cancer screening tests in medicine. PSA is a protein produced by both normal and cancerous prostate cells; elevated PSA can indicate cancer, but also BPH, prostatitis (prostate inflammation), or recent ejaculation or bicycle riding.

The controversy centers on overdiagnosis and overtreatment. Many prostate cancers are slow-growing and would never cause symptoms or death if untreated — they are clinically insignificant. PSA testing detects these cancers along with genuinely aggressive ones, and the biopsy and treatment that follow screening can cause significant side effects (erectile dysfunction, urinary incontinence) for cancers that didn't need treating.

The US Preventive Services Task Force (USPSTF) changed its recommendation in 2018 from "don't screen" to "discuss individual benefits and harms" for men aged 55-69, acknowledging that the net benefit is small but present for some men. The decision is appropriately individualized: men with a family history of prostate cancer, Black men (who have higher prostate cancer incidence and mortality), and men who place high value on early cancer detection may reasonably choose to screen. Men who are averse to the potential consequences of biopsy and treatment for indolent cancers may reasonably decline.

Diet and Prostate Health: What Has Evidence

The dietary factors with the most consistent evidence for prostate health: lycopene (from cooked tomatoes, particularly tomato sauce) has been associated with reduced prostate cancer risk in multiple observational studies. Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts) contain compounds with anti-proliferative effects on prostate cancer cells in laboratory studies, with supporting epidemiological evidence. High calcium intake (particularly from supplements rather than dairy) has been associated with increased prostate cancer risk in some studies.

Selenium and vitamin E supplements, which showed promise in early studies, were found in the large SELECT trial to provide no benefit and in the vitamin E arm to slightly increase prostate cancer risk. This is the cautionary tale for prostate supplement marketing: early observational promise frequently doesn't survive rigorous trial testing.

Honest Bottom Line: BPH (non-cancerous enlarged prostate) affects most men over 60 and is manageable through lifestyle modifications and medication without affecting cancer risk. PSA screening for prostate cancer is genuinely controversial because overdiagnosis and overtreatment of slow-growing cancers is a real harm — the decision to screen is appropriately individualized based on family history, race, and values. Black men and those with family history of prostate cancer have higher risk warranting stronger consideration of screening. Lycopene and cruciferous vegetables have the most consistent evidence for dietary prostate health; selenium and vitamin E supplements have not held up in trials.